1.
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independe...
by Chan, Francis K L, Prof
The Lancet (British edition), 2017, Vol.389 (10087), p.2375-2382
2.
Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial
by Malmstrom, Kerstin
Clinical therapeutics, 1999, Vol.21 (10), p.1653-1663
3.
Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib
by Hochberg, Marc C Marc C
Annals of the rheumatic diseases, 2015, Vol.75 (1), p.37-44
4.
A Randomized, Double-Blind Placebo-Controlled Trial on Effectiveness and Safety of Celecoxib Adjunctive Therapy in Adolescents with Acute Bipolar Mania
by Mousavi, Seyed Yaser
Journal of child and adolescent psychopharmacology, 2017, Vol.27 (6), p.494-500
5.
Efficacy and Safety Profile of Celecoxib for Treating Advanced Cancers: A Meta-analysis of 11 Randomized Clinical Trials
by Chen, Jian, PharmD, PhD
Clinical therapeutics, 2014, Vol.36 (8), p.1253-1263
6.
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
by Chalabi, Myriam
Nature medicine, 2020, Vol.26 (4), p.566-576
7.
Efficacy and Safety of Zhuanggu Joint Capsules in Combination with Celecoxib in Knee Osteoarthritis： A Multi-center, Randomized, Double-blind, Double-dummy, and Parallel Controlled...
by Zhang, Xian-Long
Chinese medical journal, 2016, Vol.129 (8), p.891-897
8.
Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth
by Gowda, Raghavendra
Cancer letters, 2016, Vol.385, p.243-250
9.
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production
by Golde, Todd E
Nature medicine, 2005, Vol.11 (5), p.545-550
10.
The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer
by Brizzolara, Antonella
Cancer letters, 2017, Vol.400, p.9-17
11.
Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain
by Schnitzer, Thomas J
Annals of the rheumatic diseases, 2015, Vol.74 (6), p.1202-1211
12.
Preoperative pain measures ineffective in outpatient abdominal surgeries
by Wright, Robert
The American journal of surgery, 2018, Vol.215 (5), p.958-962
13.
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2
by Lyons, Traci R
Nature medicine, 2011, Vol.17 (9), p.1109-1115
14.
Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection
by Chen, Jonathan H
Nature medicine, 2015, Vol.21 (4), p.327-334
15.
Drug repurposing in oncology
by Bouche, Gauthier
The lancet oncology, 2020, Vol.21 (12), p.e542-e542
16.
Targeting apoptosis pathways by Celecoxib in cancer
by Jendrossek, Verena
Cancer letters, 2011, Vol.332 (2), p.313-324
17.
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial
by Chan, Francis KL, Prof
The Lancet (British edition), 2010, Vol.376 (9736), p.173-179
18.
Evidence-based clinical practice guidelines for peptic ulcer disease 2020
by Kamada, Tomoari
Journal of gastroenterology, 2021, Vol.56 (4), p.303-322
19.
The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma
by van Roosmalen, Ingrid A. M
SpringerPlus, 2014, Vol.3 (1), p.495-495
20.
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial
by James, Nicholas D, Prof
The lancet oncology, 2012, Vol.13 (5), p.549-558
